# A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

> **NCT04897880** · PHASE2 · TERMINATED · sponsor: **Australian & New Zealand Children's Haematology/Oncology Group** · enrollment: 25 (actual)

## Conditions studied

- Rhabdoid Tumor
- Atypical Teratoid/Rhabdoid Tumor
- Malignant Rhabdoid Tumor
- Recurrent Brain Tumor, Childhood

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT04897880
- **Lead sponsor:** Australian & New Zealand Children's Haematology/Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-09
- **Primary completion:** 2024-05-08
- **Final completion:** 2024-05-08
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Drug supply
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04897880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04897880, "A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04897880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*